ETV3

Across TCGA pan-cancer cohorts, ETV3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ETV3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ETV3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ETV3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where ETV3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.443	0.883	.003	32	view →
LSCC	OS	Median	III,IV	0.551	0.914	.008	7	view →
PDAC	OS	Quartile	II,III,IV	0.514	0.934	.024	5	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ETV3–HNSC (DFS)

Open the HNSC breakdown →